Furthermore, 3-BrPA necrotic doses proved capable to dramatically reduce the constitutive expression levels of GLUT4 (featured with smaller MW) (Fig. 7b), the principal transporter of glucose uptake [54, 55], and AS160 (Akt substrate), Rab10 and Tug proteins (together with Rab2A, Rab8A and Rab14 genes), critical determinants of GLUT4 trafficking [54, 55], in T24 and T24-X (Fig. 7a and Additional file 5: Figure S5A), indicating drug’s proficiency to potently perturb glucose uptake in bladder cancer cells. This evidence concerns the gene ASPSCR1 and urinary bladder cancer.